Sign in
Taking people in United StatesNo phase

Comparing two radiation margin sizes for brain metastases treated with radiosurgery

Compares a 0mm and a 2mm radiosurgery margin in people with brain metastases.

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Registry title
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
Status
Recruiting
People taking part
180 people, planned
Started
8 Apr 2025
Expected to end
Aug 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • brain metastases radiosurgery
Record updated
30 July 2026

Who can take part

The trial is looking for adults with cancer that has spread to the brain, with tumors 4 cm (1.6 in) or less across. It compares two radiosurgery margins, 0mm and 2mm.

Age
19 years and older
Sex
All sexes
Disease stage
Brain metastases (cancer spread to the brain), each tumor no larger than 4 cm (1.6 in), and not more than twenty targets at first review.
Earlier treatment
People cannot join if they had SBRT or SRS before to a tumor planned for treatment again. Prior whole brain radiation alone is allowed. No cytotoxic chemotherapy within 3 days of treatment.
Main reasons for not taking part
  • Pregnancy
  • Unable to have MRI scans
  • Radiosurgery planned only for the cavity left after surgery
  • Diffuse leptomeningeal tumor (cancer spread widely in the brain's lining)
  • Another investigational drug within 14 days of enrollment
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 19 and older
  • Brain metastases diagnosis not requiring retreatment to the same tumor
  • For females of reproductive potential should undergo pregnancy testing as per UAB Radiation Oncology standard policies
  • Ability of subject or Legally Authorized Representative (LAR)) to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Current use of cytotoxic chemotherapy within 3 days of treatment. There are no restrictions on the use of immunotherapy during treatment. TKIs known to be radiation sensitizers such as BRAF should be held at least 24 hours prior to treatment
  • Treatment with another investigational drug 14 days of enrollment
  • Radiosurgery planned for post-operative adjuvant cavity only. Patients with any gross residual after surgery are eligible. Patients with at least one intact metastasis may enroll but adjuvant cavity will not be evaluable
  • At the time of Radiation Oncology consultation more than twenty targets are identified. Note that it is common that a few additional metastases may be identified during the treatment planning or peer review processes. More than twenty targets may be included if this number is found after the initial clinical review of the treatment planning MRI
  • Prior SBRT or SRS to a lesion planned for retreatment. Note that patients with prior whole brain radiation alone are eligible
  • Inability to have MRI imaging
  • Pregnancy
  • Tumor maximal diameter > 4 cm
  • Patients with diffuse leptomeningeal tumor are not eligible. Patients with a focal dural or pachymeningeal tumor are eligible if other intra-axial tumors are planned to be treated. Similar to postoperative cavities, the pachymeningeal tumor deposit will be treated but not evaluable for the assessment of local control or toxicity; INCLUSION OF VULNERABLE PARTICIPANTS Vulnerable populations as defined by the NIH including children, prisoners, and adult subjects who lack capacity to consent to research participation are not eligible

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Brain metastases

This trial is currently available in United States.

  • University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology CenterBirmingham, United StatesContact: John Fiveash, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.

The 2 groups in the trial

  • 0mm marginExisting treatment, for comparison

    For each patient two radiation treatment plans will be created. One will have 0 mm margin for the planning target volume. Tumors will be prescribed based upon the maximum diameter of the largest tumor and location at the discretion of the treating radiation oncologist with the following guidance: \< 2.0 cm diameter 16-20 Gy 2.0-4.0 cm diameter 3 fractions of 9 Gy for total 27 Gy.

    Treatment: brain metastases radiosurgery

  • 2mm marginExisting treatment, for comparison

    For each patient two radiation treatment plans will be created. One will be 2 mm margin for the planning target volume. Tumors will be prescribed based upon the maximum diameter of the largest tumor and location at the discretion of the treating radiation oncologist with the following guidance: \< 2.0 cm diameter 16-20 Gy 2.0-4.0 cm diameter 3 fractions of 9 Gy for total 27 Gy.

    Treatment: brain metastases radiosurgery

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
UAB 2507 - Randomized Phase II Study of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
Plain-language title
Comparing two radiation margin sizes for brain metastases treated with radiosurgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06857006, who can take part
Record updated
30 July 2026